Skip to main content

Table 1 PAF levels and metabolic enzymes of ART groups

From: In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients

Parameter Groups Baseline/0 month 1stmonth 3rdmonth 6thmonth 9thmonth 12thmonth ptime Pint.
Bound PAF (fmol/mL) T 1.66 1.11* 0.90* 1.08* 1.12 0.74* 0.010 0.357
(1.35-2.02) (0.70-1.18) (0.70-1.30) (0.70-1.54) (0.70-2.11) (0.70-1.18)
A 0.90 1.10 5.54* 1.42 1.14 1.53 0.028 P 3 = 0.038
(0.70-6.20) (0.70-2.41) (0.97-17.29) (0.78-3.85) (0.93-1.71) (0.78-2.39) P 12 = 0.083
PAF-CPT in HLs (pmol/min/mg) T 546.50 336.00* 191.50* 232.00* 338.50* 288.50* 0.009 0.304
(416.50-730.25) (182.50-451.75) (114.50-518.00) (147.25-461.25) (231.25 -381.25) (236.50-341.75)
A 344.50 257.00 438.00 344.00 495.00 445.00* 0.085
(215.25-787.75) (221.75-515.25) (183.00-535.50) (173.50-795.50) (252.50-755.00) (330.00-920.00)
Lyso-PAF-AT in HLs (pmol/min/mg) T 22.95 12.40 12.20 8.40* 13.85* 16.40* 0.002 0.818
(11.90-26.65) (10.75-33.27) (8.02-28.07) (2.22-12.92) (8.47-17.60) (9.77-19.75)
A 9.15 10.75 20.60* 10.55 13.50 12.50 0.141
(6.12-19.82) (5.25-22.20) (7.42-35.75) (6.85-27.27) (8.00-27.75) (6.50-24.25)
PAF-AH in HLs (pmol/min/mg) T 69.17 55.68 70.71 54.18* 46.32* 45.81* 0.002 0.732
(42.94-106.97) (32.34-80.52) (37.47-114.14) (33.09-65.45) (28.23-62.67) (25.79-51.56)
A 50.54 52.68 64.03* 61.30 57.05 52.24 0.180
(46.57-58.78) (34.37-72.78) (50.80-92.62) (32.55-75.06) (36.49-66.05) (40.54-61.08)
Lp-PLA2 (pmol/min/μL) T 29.35 26.15 34.20 29.10 26.40* 27.15* 0.003 0.017
(24.40-34.12) (23.70-35.37) (30.00-35.12) (26.15-38.47) (22.44-29.35) (20.79-28.50)
A 33.66 32.63 33.59 33.67 37.55* 33.33 0.002 P 3 = 0.038
(30.30-35.89) (27.20-36.59) (29.32-38.15) (27.61-35.48) (35.67-42.43) (31.63-40.90) P 12 = 0.083
  1. Group_T: tenofovir-DF/emtricitabine/ efavirenz and Group_A: abacavir/lamivudine/ efavirenz. All the results are expressed as median values and interquartile range (25th-75th). HLs: Human Leukocytes. ptime displays the difference within the group during the overall 12-month treatment.
  2. *: displays the significant difference of each time point with the baseline value (p < 0.05).
  3. Pint displays the difference between the two groups during the overall 12-month treatment.
  4. Pspecific-time-point displays the significant difference between the two groups at a specific time point.